Author:
Iyer Sunil Girish,Elias Laila,Stanchina Michele,Watts Justin
Abstract
The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective therapies targeting the mutant protein that drives the disease, leading to the chemotherapy-free approach to cure almost all patients. In this review, we discuss the paradigm of treatment of APL in 2023, reinforce the high risk of early death without prompt initiation of treatment at first clinical suspicion, and dedicate a special focus to novel agents and future directions to improve cure rates and quality of life in patients affected by APL.
Reference101 articles.
1. Patterns of leukemia incidence in the united states by subtype and demographic characteristics, 1997-2002;Yamamoto;Cancer Causes Control,2008
2. What’s new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia;Mantha;Curr Opin Hematol,2016
3. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia;Zhu;Blood.,2016
4. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab;Abaza;Blood.,2017
5. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia;Lo-Coco;N Engl J Med,2013
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献